Abeona Therapeutics Inc. Board of Directors

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

Dr. Madhav Vasanthavada M.B.A., Ph.D.

Dr. Madhav Vasanthavada M.B.A., Ph.D.

Senior VP, Chief Commercial Officer & Head of Business Development

Mr. Jon Voss

Mr. Jon Voss

VP & Head of Quality

Mr. Gregory Gin

Mr. Gregory Gin

Vice President of Investor Relations & Corporate Communications

Mr. Carl Denny

Mr. Carl Denny

Senior Vice President of Regulatory Affairs

Mr. Brian Kevany Ph.D.

Mr. Brian Kevany Ph.D.

Senior VP, CTO & CSO

Ms. Alison Hardgrove

Ms. Alison Hardgrove

Chief People Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.